Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003, for Celsion Corporation (Note: The input metadata lists "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). Celsion is a clinical-stage biotechnology company focused on developing thermotherapy systems for the treatment of cancer and benign prostatic hyperplasia (BPH). The company has no product sales and is currently conducting pivotal Phase II clinical trials for its new generation of thermotherapy products.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2003 | Six Months Ended Mar 31, 2002 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,721,838) | $(5,394,665) |
| Net Loss Attributable to Common Stockholders | $(6,827,704) | $(5,439,929) |
| Net Loss Per Share (Basic) | $(0.07) | $(0.06) |
| Operating Expenses | $6,731,053 | $5,422,649 |
| Research & Development (R&D) | $4,749,988 | $2,882,996 |
| General & Administrative (G&A) | $1,981,065 | $2,539,653 |
| Cash and Cash Equivalents (End of Period) | $3,147,324 | $3,530,096 |
| Working Capital | $3,118,573 | $735,216 (Sep 30, 2002) |
| Accumulated Deficit | $(50,647,787) | $(43,820,081) (Sep 30, 2002) |
Material Changes vs. Prior Period
- Revenue: Remained at zero; no product sales occurred in either period.
- Net Loss: Increased by approximately 25% year-over-year for the six-month period, driven primarily by higher R&D spending.
- R&D Expenses: Increased 65% to $4.75 million. This was largely due to a non-cash payment of $2.18 million (valued at 3.8 million shares of common stock) to Duke University to satisfy a license agreement obligation.
- G&A Expenses: Decreased 22% to $1.98 million. The reduction is attributed to the absence of one-time costs incurred in the prior year, including a legal settlement with Warren C. Stearns, retirement accruals for the former CEO, and consulting fees for a potential China business expansion.
- Liquidity: Cash balances increased from $928,819 at the end of the prior fiscal year (Sep 30, 2002) to $3.15 million at March 31, 2003, primarily due to financing activities.
Guidance, Outlook, and Risks
Outlook and Funding: Management expects to incur operating losses for the foreseeable future. The company projects total expenditures of approximately $8.5 million for fiscal year 2003 to fund clinical testing and overhead. These funds are expected to be covered by current resources following a strategic partnership with Boston Scientific Corporation.
Strategic Partnership: On January 21, 2003, Celsion entered an agreement with Boston Scientific Corporation. Boston Scientific purchased 9.38 million shares for $5 million and agreed to invest an additional $10 million upon meeting certain milestones. This partnership includes the marketing and distribution of Celsion's BPH treatment system.
Risks and Contingencies:
- Capital Dependence: The company has no committed sources of financing beyond the Boston Scientific agreement and must raise additional capital to continue operations. Failure to secure funding could force the company to delay or eliminate operations.
- Regulatory Approval: No product revenues are expected until the company receives necessary governmental regulatory approvals for its new equipment.
- Licensing Obligations: Inability to fund clinical trials required by licensing agreements could result in a breach of contract and loss of license rights.
Investor Verification Checklist
- Capital Adequacy: Verify if the $5 million from Boston Scientific and existing cash reserves are sufficient to fund the projected $8.5 million burn rate for the remainder of fiscal 2003.
- Clinical Trial Status: Confirm the current status and timeline of the pivotal Phase II clinical trials for the breast cancer and BPH treatment systems.
- Stock Dilution: Review the impact of the 13.1 million shares issued during the quarter (to Duke University, Boston Scientific, and consultants) on existing shareholder equity.
- Regulatory Milestones: Assess the timeline for FDA or other regulatory approvals required to generate revenue.
- Preferred Stock Obligations: Monitor the dividend requirements for Series A and Series B Convertible Preferred Stock, which increased in the current period.